Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | LPL | P06858 | 5/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1825954 | 0.84 | LPL (0.65) | ALPLLPLLIPGPDGFRBCYP2A6 | |
| SCHEMBL29831910 | 0.84 | LPL (0.50) | ALPLLPLLIPGCYP1A2PDGFRB | |
| SCHEMBL29847497 | 0.84 | LPL (0.50) | ALPLLPLLIPGCYP1A2PDGFRB | |
| SCHEMBL19106677 | 0.84 | LPL (0.50) | ALPLLPLLIPGCYP1A2PDGFRB | |
| SCHEMBL12731574 | 0.83 | DGAT1 (0.53) | ALPLLPLLIPGCYP1A2PDGFRB | |
| SCHEMBL27349470 | 0.83 | LIPG (0.56) | ALPLLPLLIPGPDGFRBKDR | |
| SCHEMBL19106599 | 0.82 | LPL (0.58) | ALPLLPLLIPGPDGFRBALDH1A1 | |
| SCHEMBL14926830 | 0.81 | ALPL (0.42) | ALPLLPLLIPGCYP1A2PDGFRB | |
| SCHEMBL14983523 | 0.81 | CYP1A2 (0.50) | ALPLCYP1A2PDGFRBALDH1A1CYP2A6 | |
| SCHEMBL23487533 | 0.81 | LPL (0.47) | ALPLLPLLIPGCYP1A2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084934-A | Fluorescent probe for detecting NADH, preparation method and biological application thereof | 天津理工大学 | 2024-05-28 | — | — | CN | claimed |
| CN-113957441-B | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-113957441-A | Etching solution and preparation method and application thereof | 光华科学技术研究院(广东)有限公司 | 2022-01-21 | — | — | CN | claimed |
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | ALLIANTHERA BOSTON INC. | 2025-05-01 | — | — | US | disclosed |
| CN-117105936-B | Imidazo [1,2-a ] pyridine compound serving as FLT3 inhibitor, and preparation method and application thereof | 遵义医科大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | DONG WHA PHARM. CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| EP-4430028-A2 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| CN-118084778-A | Preparation method of 3-hydroxyquinoline | 甘肃汇健药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084934-A | Fluorescent probe for detecting NADH, preparation method and biological application thereof | 天津理工大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20240116914-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAID COMPOUND | HODOGAYA CHEMICAL CO., LTD. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2024020170-A1 | ARYL HYDROCARBON RECEPTOR AGONIST PRODRUGS AND METHODS OF USE THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-01-25 | — | — | WO | disclosed |
| WO-2009042607-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| EP-1926729-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007038074-A1 | BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070066588-A1 | Benzothiazole cyclobutyl amine derivatives | ABBVIE INC. | 2007-03-22 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136556-A1 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | AHR, ARNT, NR1H2 | ALPL 2931/4885LPL 832/4885LIPG 1921/4885 |
| US-20240368104-A1 | Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same | IL5, ACE2, IL15 | ALPL 3584/4885LPL 3407/4885LIPG 3149/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | ALPL 198/4885LPL 2994/4885LIPG 4113/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | ALPL 3082/4885LPL 3598/4885LIPG 2592/4885 |
| US-20070066588-A1 | Benzothiazole cyclobutyl amine derivatives | HRH2, HRH4, HRH1 | ALPL 4765/4885LPL 3549/4885LIPG 2740/4885 |
| US-20240116914-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAID COMPOUND | LEF1, ELP1, EEF1A1 | ALPL 1594/4885LPL 991/4885LIPG 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.